Welcome to our dedicated page for IDEXX Laboratories SEC filings (Ticker: IDXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IDEXX Laboratories SEC filings document the formal record for a Nasdaq-listed animal-health diagnostics and software company. Form 8-K reports furnish quarterly and annual financial results, operating updates and exhibits tied to the company’s CAG Diagnostics, reference laboratory and veterinary product businesses.
The company’s filings also cover governance and capital-structure matters, including definitive proxy materials, executive compensation, board composition, officer transitions, equity-award disclosures and shareholder meeting items. Other material-event reports describe credit agreement amendments and registered common stock information, providing formal disclosure on IDEXX’s financing arrangements, corporate governance and reporting obligations.
IDEXX Laboratories director Irene Britt Chang reported equity awards in the form of stock options and deferred stock units. She received 525 non-qualified stock options with an exercise price of $533.92 per share and 234 deferred stock units, both as compensation grants. Following these awards, she holds 753 deferred stock units and 525 stock options directly, which vest in a single installment tied to the one-year anniversary of grant or the 2027 annual shareholder meeting.
IDEXX Laboratories director Sophie V. Vandebroek reported the vesting of restricted stock units and the resulting common share holdings. On May 7, 2026, 257 restricted stock units vested and converted into 257 shares of common stock at a stated price of $0.00 per share.
After this derivative exercise, Vandebroek directly holds 905 shares of common stock and indirectly holds 8,173 shares through the Sophie V. Vandebroek Revocable Trust. The filing shows no open-market purchases or sales, only equity compensation vesting and updated ownership totals.
IDEXX Laboratories director M. Anne Szostak increased her equity exposure through a routine equity award vesting. On May 7, 2026, restricted stock units covering 257 shares of common stock converted into 257 directly held shares at an exercise price of $0.00 per share, bringing her direct common stock holdings to 519 shares. She also reports indirect ownership of 1,542 shares held by the Trust of M. Anne Szostak and 259 shares held by The O'Hanian-Szostak Family Foundation, reflecting additional positions managed through these entities.
IDEXX Laboratories director Karen Peacock reported a routine equity compensation event. On May 7, 2026, she exercised 101 Restricted Stock Units, receiving 101 shares of common stock at an exercise price of $0.00 per share. Following this vesting and conversion, she directly holds 102 shares of common stock. No shares were sold and no tax-withholding dispositions were reported in this filing.
IDEXX Laboratories director Lawrence D. Kingsley reported the vesting and exercise of restricted stock units into common shares. On May 7, 2026, 82 and 257 restricted stock units each converted into the same number of IDEXX common shares at a stated price of $0.00 per share.
Each restricted stock unit represented a right to receive one share of common stock that vested in a single installment on May 7, 2026. The filing shows only derivative exercises and conversions, with no open-market purchases or sales. These transactions reflect compensation-related equity vesting rather than discretionary trading.
Director Daniel M. Junius of IDEXX Laboratories reported a routine equity compensation event. On May 7, 2026, a grant of 257 restricted stock units vested, converting into 257 shares of common stock. After this vesting and conversion, he directly holds 3,561 shares of IDEXX common stock.
IDEXX Laboratories director Joseph L. Hooley reported a routine equity compensation event. On May 7, 2026, 158 restricted stock units vested and were converted into 158 shares of IDEXX common stock, with no sale involved.
Following this exercise and conversion of the derivative security, Hooley directly holds 276 shares of common stock. The vested RSUs represented a contingent right to receive one share of common stock per unit, vesting in a single installment on May 7, 2026.
IDEXX Laboratories reported solid growth for the quarter ended March 31, 2026. Total revenue rose to $1.14 billion from $998.4 million a year earlier, driven mainly by higher Companion Animal Group diagnostic and software revenues and broader international demand.
Net income increased to $278.4 million from $242.7 million, with diluted earnings per share up to $3.47 from $2.96. Operating cash flow was strong at $266.2 million, supporting continued investment and capital returns, including $360.8 million of open-market share repurchases and ongoing use of the company’s credit facility and senior notes.
IDEXX Laboratories reported strong first quarter 2026 results, with revenue of $1.14 billion, up 14% as reported and 11% organically. Growth was led by Companion Animal Group revenue, including 14% reported and 11% organic CAG Diagnostics recurring revenue growth, and 33% reported growth in diagnostics capital instruments.
Diluted EPS was $3.47, up 17% as reported and 15% on a comparable basis. Gross margin improved to 63.4% and operating margin to 31.8%. Free cash flow was $234 million. Management raised full-year 2026 guidance, targeting revenue of $4.675–$4.760 billion, organic growth of 7.7%–9.7%, and EPS of $14.45–$14.90.
IDEXX Laboratories director Joseph L. Hooley acquired 43 deferred stock units tied to the company’s common stock as a compensation award. The units were valued using a reference price of $560.80 per share, reflecting the conversion of $24,375.00 of cash compensation he chose to defer.
Each deferred stock unit represents the right to receive one IDEXX share in the future. The units vest immediately and will be settled in stock after Hooley leaves the Board or on another fixed date allowed under the director plan. Following this grant, he directly holds 118 deferred stock units.